To- års overlevelsesraterne var 50, 8% hos patienter, der fik azacitidin kontra 26, 2% for patienter, der fik CCR (p < 0, 0001).
The two-year survival rates were 50.8% in patients receiving azacitidine versus 26.2% in patients receiving CCR (p < 0.0001).